A randomized double-blind placebo-controlled dose ranging phase 2 study of ISIS 681257 administered subcutaneously to patients with hyperlipoproteinemia(a) and established cardiovascular disease (CVD)
-
- STATUS
- None
Updated on 19 February 2024
Summary
A phase 2 randomized, double-blind, placebo-controlled, dose-ranging study in patients with Hyperlipoproteinemia(a) and established cardiovascular disease. The study consists of 3 periods: screening, treatment period, and follow-up. Subjects will have 21 visits over a 6 to 12 month period. Procedures include blood draws, genetic testing, diet counseling, SC drug administration, blood collection, ECG, QoL, and physical.
Details
| Condition | TBD, tbd, tbd |
|---|---|
| Age | 99years or below |
| Clinical Study Identifier | 03070782 |
| Last Modified on | 19 February 2024 |
How understandable was the trial content above?
Hard to understand
Easy to understand
Similar trials to consider
Loading...
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteerStudy Definition
WikipediaAdd a private note
- Select a piece of text.
- Add notes visible only to you.
- Send it to people through a passcode protected link.